Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus CHLOROPTIC P S O P.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus CHLOROPTIC P S O P.
CHLOROMYXIN vs CHLOROPTIC-P S.O.P.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Chloroptic-P S.O.P. contains prednisolone acetate and chloramphenicol. Prednisolone acetate is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Chloramphenicol is a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
Adults: Instill 1/2-inch ribbon into conjunctival sac 3-4 times daily, or more frequently as needed. Not for injection.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life: 2-4 hours (systemic); prolonged to 21-24 hours in severe hepatic impairment. Clinical context: short half-life supports 2-3 times daily dosing.
CHLOROMYXIN is not a recognized drug. No data available.
Renal: 50-70% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites; small amount via lacrimal drainage after ophthalmic administration.
Category C
Category C
Antibiotic
Antibiotic